Litcius/Paper detail

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha H. Shah, Ronnie Shapira‐Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L. Kindler, José A. López-Martín, Wilson H. Miller, Antoîne Italiano, Steven Kao, Sarina A. Piha‐Paul, Jean‐Pierre Delord, Robert R. McWilliams, David Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung‐Jue Bang

2020The Lancet Oncology2,494 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePembrolizumabInternal medicineResponse Evaluation Criteria in Solid TumorsOncologyCohortMesotheliomaBiomarkerClinical endpointProspective cohort studyCancerProgressive diseaseDiseaseImmunotherapyPathologyClinical trialBiochemistryChemistryCancer Immunotherapy and BiomarkersMultiple and Secondary Primary CancersColorectal and Anal Carcinomas
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study | Litcius